New Fundamentals in hemostasis

Physiological Reviews

Volumn 93, Issue 1, 2013, Pages 327-358

  Versteeg, Henri H ^a,b,c   Heemskerk, Johan W M ^a,b,c   Levi, Marcel ^a,b,c   Reitsma, Pieter H ^a,b,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; IMMUNOGLOBULIN RECEPTOR; INTEGRIN; PROTEIN C; PROTEIN S; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR; THROMBIN;

ANTICOAGULATION; BLOOD CLOTTING; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEMOSTASIS; HUMAN; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBUS; VENOUS THROMBOEMBOLISM; WOUND HEALING;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; CELL COMMUNICATION; FEEDBACK, PHYSIOLOGICAL; HEMOSTASIS; HUMANS; PLATELET ACTIVATION; SIGNAL TRANSDUCTION;

EID: 84872288751     PISSN: 00319333     EISSN: 15221210     Source Type: Journal    
DOI: 10.1152/physrev.00016.2011     Document Type: Review

References (332)

1. Ahamed J, Ruf W. Protease-activated receptor 2-dependent phosphorylation of the tissue factor cytoplasmic domain. J Biol Chem 279: 23038-23044, 2004.
2. Ahamed J, Versteeg HH, Kerver M, Chen VM, Mueller BM, Hogg PJ, Ruf W. Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA 103: 13932-13937, 2006.
3. Akagi S, Yamamoto A, Yoshimori T, Masaki R, Ogawa R, Tashiro Y. Localization of protein disulfide isomerase on plasma membranes of rat exocrine pancreatic cells. J Histochem Cytochem 36: 1069-1074, 1988.
4. Al-Tamimi M, Grigoriadis G, Tran H, Paul E, Servadei P, Berndt MC, Gardiner EE, Andrews RK. Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 117: 3912-3920, 2011.
5. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Proteaseactivated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 96: 11189-11193, 1999.
6. Andrews RK, Berndt MC, Lopez JA. The glycoprotein Ib-IX-V complex. In: Platelets. Burlington: Academic, 2007, p. 145-163.
7. Andrews RK, Karunakaran D, Gardiner EE, Berndt MC. Platelet receptor proteolysis: a mechanism for downregulating platelet reactivity. Arterioscler Thromb Vasc Biol 27: 1511-1520, 2007.
8. Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 100: 743-754, 2002.
9. Arya M, Anvari B, Romo GM, Cruz MA, Dong JF, McIntire LV, Moake JL, Lopez JA. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 99: 3971-3977, 2002.
10. Auger JM, Kuijpers MJ, Senis YA, Watson SP, Heemskerk JW. Adhesion of human and mouse platelets to collagen under shear: a unifying model. FASEB J 19: 825-827, 2005.
11. Auger JM, Watson SP. Dynamic tyrosine kinase-regulated signaling and actin polymerisation mediate aggregate stability under shear. Arterioscler Thromb Vasc Biol 28: 1499-1504, 2008.
12. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 87: 6995-6999, 1990.
13. Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 26: 456-461, 2006.
14. Bach RR, Moldow CF. Mechanism of tissue factor activation on HL-60 cells. Blood 89: 3270-3276, 1997.
15. Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 110: 3909-3916, 2007.
16. Bae JS, Yang L, Rezaie AR. Lipid raft localization regulates the cleavage specificity of protease activated receptor 1 in endothelial cells. J Thromb Haemost 6: 954-961, 2008.
17. Baglia FA, Shrimpton CN, Emsley J, Kitagawa K, Ruggeri ZM, Lopez JA, Walsh PN. Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet. J Biol Chem 279: 49323-49329, 2004.
18. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 271: 16603-16608, 1996.
19. Banner DW, D'Arcy A, Chène C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 380: 41-46, 1996.
20. Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 87: 6934-6938, 1990.
21. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 366: 1959-1967, 2012.
22. Beguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 93: 564-570, 1999.
23. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10: 502-509, 2004.
24. Bender M, Hofmann S, Stegner D, Chalaris A, Bosl M, Braun A, Scheller J, Rose-John S, Nieswandt B. Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood 116: 3347-3355, 2010.
25. Bergh N, Larsson P, Ulfhammer E, Jern S. Effect of shear stress, statins and TNF-alpha on hemostatic genes in human endothelial cells. Biochem Biophys Res Commun 420: 166-171, 2012.
26. Bergmeier W, Goerge T, Wang HW, Crittenden JR, Baldwin AC, Cifuni SM, Housman DE, Graybiel AM, Wagner DD. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J Clin Invest 117: 1699-1707, 2007.
27. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709, 2001.
28. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369: 64-67, 1994.
29. Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, Catanese J, Young BA, Reitsma PH, Devlin JJ, Rosendaal FR. Gene variants associated with deep vein thrombosis. JAMA 299: 1306-1314, 2008.
30. Bizzozero G. Su di un nuovo elemento morfologico del sangue dei mammiferi e della sua importanza nella trombosi e nella coagulazione. L'Osservatore 17: 3, 1881.
31. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9: 458-462, 2003.
32. Boing AN, Hau CM, Sturk A, Nieuwland R. Human alternatively spliced tissue factor is not secreted and does not trigger coagulation. J Thromb Haemost 7: 1423-1426, 2009.
33. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120: 303-313, 2005.
34. Bonnefoy A, Moura R, Hoylaerts MF. The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell Mol Life Sci 65: 713-727, 2008.
35. Brass LF, Stalker TJ, Zhu L, Woulfe DS. Signal transduction during platelet plug formation. In: Platelets, edited by Michelson AD. Burlington: Academic, 2001, p. 319-346.
36. Brass LF, Wannemacher KM, Ma P, Stalker TJ. Regulating thrombus growth and stability to achieve an optimal response to injury. J Thromb Haemost 9 Suppl 1: 66-75, 2011.
37. Bretschneider E, Spanbroek R, Lotzer K, Habenicht AJ, Schror K. Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells. Thromb Haemost 90: 704-709, 2003.
38. Brown DA, Rose JK. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell 68: 533-544, 1992.
39. Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci 17: 262-280, 2012.
40. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 71: 335-343, 1988.
41. Buensuceso CS, Arias-Salgado EG, Shattil SJ. Protein-protein interactions in platelet alphaIIbbeta3 signaling. Semin Thromb Hemost 30: 427-439, 2004.
42. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 275: 6580-6585, 2000.
43. Camire RM, Kalafatis M, Simioni P, Girolami A, Tracy PB. Platelet-derived factor Va/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood 91: 2818-2829, 1998.
44. Canobbio I, Balduini C, Torti M. Signalling through the platelet glycoprotein Ib-V-IX complex. Cell Signal 16: 1329-1344, 2004.
45. Castoldi E, Simioni P, Tormene D, Rosing J, Hackeng TM. Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost 8: 294-300, 2010.
46. Cattaneo M. Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thromb Haemost 105 Suppl 1: S67-74, 2011.
47. Censarek P, Bobbe A, Grandoch M, Schror K, Weber AA. Alternatively spliced human tissue factor (asHTF) is not pro-coagulant. Thromb Haemost 97: 11-14, 2007.
48. Chen H, Kahn ML. Reciprocal signaling by integrin and nonintegrin receptors during collagen activation of platelets. Mol Cell Biol 23: 4764-4777, 2003.
49. Cho J, Furie BC, Coughlin SR, Furie B. A critical role for extracellular protein disulfide isomerase during thrombus formation in mice. J Clin Invest 118: 1123-1131, 2008.
50. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 118: 6963-6970, 2011.
51. Cicmil M, Thomas JM, Leduc M, Bon C, Gibbins JM. Platelet endothelial cell adhesion molecule-1 signaling inhibits the activation of human platelets. Blood 99: 137-144, 2002.
52. Clemetson JM, Polgar J, Magnenat E, Wells TN, Clemetson KJ. The platelet collagen receptor glycoprotein VI is a member of the immunoglobulin superfamily closely related to FcalphaR and the natural killer receptors. J Biol Chem 274: 29019-29024, 1999.
53. Clemetson KJ, Clemetson CJ. Platelet receptors. In: Platelets. Burlington: Academic, 2007, p. 117-143.
54. Colman RWCA, George JN, Hirsh J, Marder VJ. Overview of hemostasis. In: Hemostasis and Thrombosis, Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott Williams & Wilkins, 2001, p. 3-16.
55. Cosemans JM, Iserbyt BF, Deckmyn H, Heemskerk JW. Multiple ways to switch platelet integrins on and off. J Thromb Haemost 6: 1253-1261, 2008.
56. Cosemans JM, Schols SE, Stefanini L, de Witt S, Feijge MA, Hamulyak K, Deckmyn H, Bergmeier W, Heemskerk JW. Key role of glycoprotein Ib/V/IX and von Willebrand factor in platelet activation-dependent fibrin formation at low shear flow. Blood 117: 651-660, 2011.
57. Cosemans JM, Van Kruchten R, Olieslagers S, Schurgers LJ, Verheyen FK, Munnix IC, Waltenberger J, Angelillo-Scherrer A, Hoylaerts MF, Carmeliet P, Heemskerk JW. Potentiating role of Gas6 and Tyro3, Axl and Mer (TAM) receptors in human and murine platelet activation and thrombus stabilization. J Thromb Haemost 8: 1797-1808, 2010.
58. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3: 1800-1814, 2005.
59. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 407: 258-264, 2000.
60. Csongradi E, Nagy B Jr, Fulop T, Varga Z, Karanyi Z, Magyar MT, Olah L, Papp M, Facsko A, Kappelmayer J, Paragh G, Kaplar M. Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients. Thromb Haemost 106: 683-692, 2011.
61. Dahlback B, Villoutreix BO. The anticoagulant protein C pathway. FEBS Lett 579: 3310-3316, 2005.
62. Dahlback B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol 25: 1311-1320, 2005.
63. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 3: 2185-2192, 2005.
64. Daleke DL. Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res 44: 233-242, 2003.
65. Daubie V, Cauwenberghs S, Senden NH, Pochet R, Lindhout T, Buurman WA, Heemskerk JW. Factor Xa and thrombin evoke additive calcium and proinflammatory responses in endothelial cells subjected to coagulation. Biochim Biophys Acta 1763: 860-869, 2006.
66. Davidson CJ, Hirt RP, Lal K, Snell P, Elgar G, Tuddenham EG, McVey JH. Molecular evolution of the vertebrate blood coagulation network. Thromb Haemost 89: 420-428, 2003.
67. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 145: 1310-1312, 1964.
68. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 276: 4692-4698, 2001.
69. De Pont AC, Bakhtiari K, Hutten BA, de Jonge E, Vlasuk GP, Rote WE, Levi M, Buller HR, Meijers JC. Endotoxaemia induces resistance to activated protein C in healthy humans. Br J Haematol 134: 213-219, 2006.
70. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 106: 1604-1611, 2005.
71. Demers C, Ginsberg JS, Hirsh J, Henderson P, Blajchman MA. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 116: 754-761, 1992.
72. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 87: 6306-6310, 1990.
73. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, Sundin DP, Levi M. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2: 1924-1933, 2004.
74. Disse J, Petersen HH, Larsen KS, Persson E, Esmon N, Esmon CT, Teyton L, Petersen LC, Ruf W. The endothelial protein C receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem 286: 5756-5767, 2011.
75. Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Cross-talk of integrin alpha3beta1 and tissue factor in cell migration. Mol Biol Cell 15: 4416-4425, 2004.
76. Dorfleutner A, Ruf W. Regulation of tissue factor cytoplasmic domain phosphorylation by palmitoylation. Blood 102: 3998-4005, 2003.
77. Drake TA, Cheng J, Chang A, Taylor FB Jr. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal E. coli sepsis. Am J Pathol 142: 1458-1470, 1993.
78. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 134: 1087-1097, 1989.
79. Dubois C, Atkinson B, Furie BA, Furie B. Real-time in vivo imaging of platelets during thrombus formation. In: Platelets. Burlington: Academic, 2007, p. 611-626.
80. Dudzinski DM, Igarashi J, Greif D, Michel TM. The regulation and pharmacology of endothelial nitric oxide synthases. Annu Rev Pharmacol Toxicol 46: 235-276, 2005.
81. Eckle I, Seitz R, Egbring R, Kolb G, Havemann K. Protein C degradation in vitro by neutrophil elastase. Biol Chem Hoppe Seyler 372: 1007-1013, 1991.
82. Elvers M, Stegner D, Hagedorn I, Kleinschnitz C, Braun A, Kuijpers ME, Boesl M, Chen Q, Heemskerk JW, Stoll G, Frohman MA, Nieswandt B. Impaired alpha(IIb) beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1. Sci Signal 3: ra1, 2010.
83. Emsley J, Knight CG, Farndale RW, Barnes MJ, Liddington RC. Structural basis of collagen recognition by integrin alpha2beta1. Cell 101: 47-56, 2000.
84. Erlich J, Fearns C, Mathison J, Ulevitch RJ, Mackman N. Lipopolysaccharide induction of tissue factor expression in rabbits. Infection Immunity 67: 2540-2546, 1999.
85. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 86: 51-56, 2001.
86. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264: 4743-4746, 1989.
87. Essex DW, Chen K, Swiatkowska M. Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane. Blood 86: 2168-2173, 1995.
88. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 197: 1585-1598, 2003.
89. Falati S, Patil S, Gross PL, Stapleton M, Merrill-Skoloff G, Barrett NE, Pixton KL, Weiler H, Cooley B, Newman DK, Newman PJ, Furie BC, Furie B, Gibbins JM. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 107: 535-541, 2006.
90. Farndale RW, Slatter DA, Siljander PR, Jarvis GE. Platelet receptor recognition and cross-talk in collagen-induced activation of platelets. J Thromb Haemost 5 Suppl 1: 220-229, 2007.
91. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345: 408-416, 2001.
92. Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 269: 20522-20527, 1994.
93. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105: 3178-3184, 2005.
94. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 280: 17286-17293, 2005.
95. Freyssinet JM, Toti F. Formation of procoagulant microparticles and properties. Thromb Res 125 Suppl 1: S46-48, 2010.
96. Fukudome K, Esmon CT. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 269: 26486-26491, 1994.
97. 2 responses of human platelets. Thromb Haemost 94: 37-40, 2005.
98. Furlan-Freguia C, Marchese P, Gruber A, Ruggeri ZM, Ruf W. P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J Clin Invest 121: 2932-2944, 2011.
99. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339: 1578-1584, 1998.
100. Ghosh S, Pendurthi UR, Steinoe A, Esmon CT, Rao LV. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 282: 11849-11857, 2007.
101. Gibbins JM. Platelet adhesion signalling and the regulation of thrombus formation. J Cell Sci 117: 3415-3425, 2004.
102. Giesen PL, Rauch U, Bohrmann B, Kling D, Roqué M, Fallon JT, Badimon JJ, Himber J, Riederer M, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 96: 2311-2315, 1999.
103. Gilio K, van Kruchten R, Braun A, Berna-Erro A, Feijge MA, Stegner D, van der Meijden PE, Kuijpers MJ, Varga-Szabo D, Heemskerk JW, Nieswandt B. Roles of platelet STIM1 and Orai1 in glycoprotein VI- and thrombin-dependent procoagulant activity and thrombus formation. J Biol Chem 285: 23629-23638, 2010.
104. Girard TJ, Tuley E, Broze GJ Jr. TFPIbeta is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes. Blood 119: 1256-1262, 2012.
105. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338: 518-520, 1989.
106. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360: 1851-1861, 2009.
107. Goldin-Lang P, Tran QV, Fichtner I, Eisenreich A, Antoniak S, Schulze K, Coupland SE, Poller W, Schultheiss HP, Rauch U. Tissue factor expression pattern in human nonsmall cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol Rep 20: 123-128, 2008.
108. Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 75: 281-289, 1996.
109. Gruner S, Prostredna M, Schulte V, Krieg T, Eckes B, Brakebusch C, Nieswandt B. Multiple integrin-ligand interactions synergize in shear-resistant platelet adhesion at sites of arterial injury in vivo. Blood 102: 4021-4027, 2003.
110. Gu JM, Crawley JT, Ferrell G, Zhang F, Li W, Esmon NL, Esmon CT. Disruption of the endothelial cell protein C receptor gene in mice causes placental thrombosis and early embryonic lethality. J Biol Chem 277: 43335-43343, 2002.
111. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 103: 3106-3111, 2006.
112. Hagiwara S, Iwasaka H, Matsumoto S, Hasegawa A, Yasuda N, Noguchi T. In vivo and in vitro effects of the anticoagulant, thrombomodulin, on the inflammatory response in rodent models. Shock 33: 282-288, 2010.
113. Halvorsen J, Olsen JO, Osterud B. Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with platelets. J Leukoc Biol 54: 275-282, 1993.
114. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 14: 223-229, 1994.
115. 2 entry and phosphatidylserine exposure downstream of glycoprotein VI in platelets. J Biol Chem 285: 19865-19873, 2010.
116. Hawiger J. Adhesive interactions of blood cells and the vascular wall in hemostasis and thrombosis. In: Hemostasis and Thrombosis, Basic Principles and Clinical Practice, edited by RW Colman JH, VJ Marder, AW Clowes, JN George. Philadelphia, PA: Lippincott Williams & Wilkins, 2001, p. 639-660.
117. Hechler B, Gachet C. P2 receptors and platelet function. Purinergic Signal 7: 293-303, 2011.
118. Hechler B, Nonne C, Eckly A, Magnenat S, Rinckel JY, Denis CV, Freund M, Cazenave JP, Lanza F, Gachet C. Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost 8: 173-184, 2010.
119. Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 268: 2872-2877, 1993.
120. Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 91: 2728-2732, 1994.
121. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemost 88: 186-193, 2002.
122. Heemskerk JW, Harper MT, Cosemans JM, Poole AW. Unravelling the different functions of protein kinase C isoforms in platelets. FEBS Lett 585: 1711-1716, 2011.
123. Heemskerk JW, Hoyland J, Mason WT, Sage SO. Spiking in cytosolic calcium concentration in single fibrinogen-bound fura-2-loaded human platelets. Biochem J 283: 379-383, 1992.
124. Hemler ME. VLA proteins in the integrin family: structures, functions, and their role on leukocytes. Annu Rev Immunol 8: 365-400, 1990.
125. Higure A, Okamoto K, Hirata K, Todoroki H, Nagafuchi Y, Takeda S, Katoh H, Itoh H, Ohsato K, Nakamura S. Macrophages and neutrophils infiltrating into the liver are responsible for tissue factor expression in a rabbit model of acute obstructive cholangitis. Thromb Haemost 75: 791-795, 1996.
126. Hoffman M, Monroe DM. The multiple roles of tissue factor in wound healing. Front Biosci 4: 713-721, 2012.
127. Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH Jr, Schaub RG, McEver RP, Wagner DD. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med 9: 1020-1025, 2003.
128. Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ, Gros P. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 297: 1176-1179, 2002.
129. Huntington JA. Serpin structure, function and dysfunction. J Thromb Haemost 9 Suppl 1: 26-34, 2011.
130. Inoue O, Suzuki-Inoue K, Ozaki Y. Redundant mechanism of platelet adhesion to laminin and collagen under flow: involvement of von Willebrand factor and glycoprotein Ib-IX-V. J Biol Chem 283: 16279-16282, 2008.
131. Ishiguro K, Kojima T, Kadomatsu K, Nakayama Y, Takagi A, Suzuki M, Takeda N, Ito M, Yamamoto K, Matsushita T, Kusugami K, Muramatsu T, Saito H. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 106: 873-878, 2000.
132. Jackson SP, Mistry N, Yuan Y. Platelets and the injured vessel wall "rolling into action": focus on glycoprotein Ib/V/IX and the platelet cytoskeleton. Trends Cardiovasc Med 10: 192-197, 2000.
133. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 1: 1602-1612, 2003.
134. Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 11: 507-514, 2005.
135. Jesty J. The inhibition of activated bovine coagulation factors X and VII by antithrombin III. Arch Biochem Biophys 185: 165-173, 1978.
136. Johnson GJ, Leis LA, Bach RR. Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty. Thromb Haemost 102: 728-734, 2009.
137. Jurk K, Clemetson KJ, de Groot PG, Brodde MF, Steiner M, Savion N, Varon D, Sixma JJ, Van Aken H, Kehrel BE. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J 17: 1490-1492, 2003.
138. Kalafatis M, Beck DO. Identification of a binding site for blood coagulation factor Xa on the heavy chain of factor Va. Amino acid residues 323-331 of factor V represent an interactive site for activated factor X. Biochemistry 41: 12715-12728, 2002.
139. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 269: 31869-31880, 1994.
140. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Gunther A, Engelmann B, Preissner KT. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 104: 6388-6393, 2007.
141. Kehrel B, Kronenberg A, Rauterberg J, Niesing-Bresch D, Niehues U, Kardoeus J, Schwippert B, Tschope D, van de Loo J, Clemetson KJ. Platelets deficient in glycoprotein IIIb aggregate normally to collagens type I and III but not to collagen type V. Blood 82: 3364-3370, 1993.
142. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ, Mackman N, Griffin JH, Weiler H. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 204: 2439-2448, 2007.
143. Klarenbach SW, Chipiuk A, Nelson RC, Hollenberg MD, Murray AG. Differential actions of PAR2 and PAR1 in stimulating human endothelial cell exocytosis and permeability: the role of Rho-GTPases. Circ Res 92: 272-278, 2003.
144. Kokame K, Zheng X, Sadler JE. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C. J Biol Chem 273: 12135-12139, 1998.
145. Konopatskaya O, Matthews SA, Harper MT, Gilio K, Cosemans JM, Williams CM, Navarro MN, Carter DA, Heemskerk JW, Leitges M, Cantrell D, Poole AW. Protein kinase C mediates platelet secretion and thrombus formation through protein kinase D2. Blood 118: 416-424, 2011.
146. Koutsi A, Papapanagiotou A, Papavassiliou AG. Thrombomodulin: from haemostasis to inflammation and tumourigenesis. Int J Biochem Cell Biol 40: 1669-1673, 2008.
147. Kronstein R, Seebach J, Grossklaus S, Minten C, Engelhardt B, Drab M, Liebner S, Arsenijevic Y, Taha AA, Afanasieva T, Schnittler HJ. Caveolin-1 opens endothelial cell junctions by targeting catenins. Cardiovasc Res 93: 130-140, 2012.
148. Kuijpers MJ, Schulte V, Bergmeier W, Lindhout T, Brakebusch C, Offermanns S, Fassler R, Heemskerk JW, Nieswandt B. Complementary roles of glycoprotein VI and alpha2beta1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo. FASEB J 17: 685-687, 2003.
149. Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 38: 4572-4585, 1999.
150. Kunzelmann-Marche C, Satta N, Toti F, Zhang Y, Nawroth PP, Morrissey JH, Freyssinet JM. The influence exerted by a restricted phospholipid microenvironment on the expression of tissue factor activity at the cell plasma membrane surface. Thromb Haemost 83: 282-289, 2000.
151. Langer F, Morys-Wortmann C, Küsters B, Storck J. Endothelial protease-activated receptor-2 induces tissue factor expression and von Willebrand factor release. Br J Haematol 105: 541-550, 1999.
152. Laszik Z, Mitro A, Taylor FB Jr, Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway. Circulation 96: 3633-3640, 1997.
153. Laurens N, Koolwijk P, de Maat MP. Fibrin structure and wound healing. J Thromb Haemost 4: 932-939, 2006.
154. Lawrence DA, Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman JO, Shore JD. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 270: 25309-25312, 1995.
155. Le DT, Rapaport SI, Rao LVM. Relations between factor VIIa binding and expression of factor VIIa/tissue factor catalytic activity on cell surfaces. J Biol Chem 267: 15447-15454, 1992.
156. Lenting PJ, Pegon JN, Groot E, de Groot PG. Regulation of von Willebrand factorplatelet interactions. Thromb Haemost 104: 449-455, 2010.
157. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 82: 695-705, 1999.
158. Levi M, van der Poll T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin Thromb Hemost 34: 459-468, 2008.
159. Lhermusier T, van Rottem J, Garcia C, Xuereb JM, Ragab A, Martin V, Gratacap MP, Sie P, Payrastre B. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. J Thromb Haemost 9: 2067-2076, 2011.
160. Li W, Johnson DJ, Esmon CT, Huntington JA. Structure of the antithrombin-thrombinheparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 11: 857-862, 2004.
161. Lievens D, Zernecke A, Seijkens T, Soehnlein O, Beckers L, Munnix IC, Wijnands E, Goossens P, van Kruchten R, Thevissen L, Boon L, Flavell RA, Noelle RJ, Gerdes N, Biessen EA, Daemen MJ, Heemskerk JW, Weber C, Lutgens E. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 116: 4317-4327, 2010.
162. Lillicrap D. Genotype/phenotype association in von Willebrand disease: is the glass half full or empty? J Thromb Haemost 7 Suppl 1: 65-70, 2009.
163. Liu LW, Vu TKH, Esmon CT, Coughlin SR. The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. J Biol Chem 266: 16977-16980, 1991.
164. Lohi O, Urban S, Freeman M. Diverse substrate recognition mechanisms for rhomboids: thrombomodulin is cleaved by mammalian rhomboids. Curr Biol 14: 236-241, 2004.
165. Lopez-Sagaseta J, Montes R, Puy C, Diez N, Fukudome K, Hermida J. Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity. J Thromb Haemost 5: 1817-1824, 2007.
166. Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 439-456, 2004.
167. Ludeman MJ, Kataoka H, Srinivasan Y, Esmon NL, Esmon CT, Coughlin SR. PAR1 cleavage and signaling in response to activated protein C and thrombin. J Biol Chem 280: 13122-13128, 2005.
168. Macfarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 202: 498-499, 1964.
169. Mackman N. New insights into the mechanisms of venous thrombosis. J Clin Invest 122: 2331-2336, 2012.
170. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 108: 1447-1452, 2009.
171. Mandal SK, Iakhiaev A, Pendurthi UR, Rao LV. Acute cholesterol depletion impairs functional expression of tissue factor in fibroblasts: modulation of tissue factor activity by membrane cholesterol. Blood 105: 153-160, 2005.
172. Mann KG, Hockin MF, Begin KJ, Kalafatis M. Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J Biol Chem 272: 20678-20683, 1997.
173. Maurer LM, Tomasini-Johansson BR, Mosher DF. Emerging roles of fibronectin in thrombosis. Thromb Res 125: 287-291, 2010.
174. Maurissen LF, Thomassen MC, Nicolaes GA, Dahlback B, Tans G, Rosing J, Hackeng TM. Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. Blood 111: 3034-3041, 2008.
175. May F, Hagedorn I, Pleines I, Bender M, Vogtle T, Eble J, Elvers M, Nieswandt B. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 114: 3464-3472, 2009.
176. Maynard JR, Heckman CA, Pitlick FA, Nemerson Y. Association of tissue factor activity with the surface of cultured cells. J Clin Invest 55: 814-824, 1975.
177. Moake J. Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol 22: 567-576, 2009.
178. Moers A, Nieswandt B, Massberg S, Wettschureck N, Gruner S, Konrad I, Schulte V, Aktas B, Gratacap MP, Simon MI, Gawaz M, Offermanns S. G13 is an essential mediator of platelet activation in hemostasis and thrombosis. Nat Med 9: 1418-1422, 2003.
179. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 26: 41-48, 2006.
180. Montgomery RR. Structure and function of von Willebrand factor. In: Hemostasis and Thrombosis, Basic Principles and Clinical Practice, edited by RW Colman, VJ Marder, AW Clowes, JN George. Philadelphia, PA: Lippincott Williams & Wilkins, 2007, p. 249-274.
181. Mori J, Pearce AC, Spalton JC, Grygielska B, Eble JA, Tomlinson MG, Senis YA, Watson SP. G6b-B inhibits constitutive and agonist-induced signaling by glycoprotein VI and CLEC-2. J Biol Chem 283: 35419-35427, 2008.
182. Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 84: 1440-1445, 1989.
183. Moroi M, Onitsuka I, Imaizumi T, Jung SM. Involvement of activated integrin alpha2beta1 in the firm adhesion of platelets onto a surface of immobilized collagen under flow conditions. Thromb Haemost 83: 769-776, 2000.
184. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renne T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139: 1143-1156, 2009.
185. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 17: 476-478, 2003.
186. Munnix IC, Cosemans JM, Auger JM, Heemskerk JW. Platelet response heterogeneity in thrombus formation. Thromb Haemost 102: 1149-1156, 2009.
187. Munnix IC, Gilio K, Siljander PR, Raynal N, Feijge MA, Hackeng TM, Deckmyn H, Smethurst PA, Farndale RW, Heemskerk JW. Collagen-mimetic peptides mediate flow-dependent thrombus formation by high- or low-affinity binding of integrin alpha2beta1 and glycoprotein VI. J Thromb Haemost 6: 2132-2142, 2008.
188. Munnix IC, Kuijpers MJ, Auger J, Thomassen CM, Panizzi P, van Zandvoort MA, Rosing J, Bock PE, Watson SP, Heemskerk JW. Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol 27: 2484-2490, 2007.
189. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5: 692-699, 2007.
190. Nagashima M, Lundh E, Leonard JC, Morser J, Parkinson JF. Alanine-scanning mutagenesis of the epidermal growth factor-like domains of human thrombomodulin identifies critical residues for its cofactor activity. J Biol Chem 268: 2888-2892, 1993.
191. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, Weiss EJ, Ludeman MJ, Coughlin SR. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404: 609-613, 2000.
192. Navarro S, Medina P, Mira Y, Estelles A, Villa P, Ferrando F, Vaya A, Bertina RM, Espana F. Haplotypes of the EPCR gene, prothrombin levels, and the risk of venous thrombosis in carriers of the prothrombin G20210A mutation. Haematologica 93: 885-891, 2008.
193. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 163: 740-745, 1986.
194. Ndonwi M, Broze G Jr. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 6: 1044-1046, 2008.
195. Ndonwi M, Tuley EA, Broze GJ Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 116: 1344-1351, 2010.
196. Nergiz-Unal R, Lamers MM, Van Kruchten R, Luiken JJ, Cosemans JM, Glatz JF, Kuijpers MJ, Heemskerk JW. Signaling role of CD36 in platelet activation and thrombus formation on immobilized thrombospondin or oxidized low-density lipoprotein. J Thromb Haemost 9: 1835-1846, 2011.
197. Nesbitt WS, Westein E, Tovar-Lopez FJ, Tolouei E, Mitchell A, Fu J, Carberry J, Fouras A, Jackson SP. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 15: 665-673, 2009.
198. Neuenschwander PF, Fiore MM, Morrissey JH. Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes. Implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 268: 21489-21492, 1993.
199. Ni H, Papalia JM, Degen JL, Wagner DD. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood 102: 3609-3614, 2003.
200. Nicolaes GA, Dahlback B. Factor V and thrombotic disease: description of a janusfaced protein. Arterioscler Thromb Vasc Biol 22: 530-538, 2002.
201. Nieswandt B, Brakebusch C, Bergmeier W, Schulte V, Bouvard D, Mokhtari-Nejad R, Lindhout T, Heemskerk JW, Zirngibl H, Fassler R. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 20: 2120-2130, 2001.
202. Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost 9 Suppl 1: 92-104, 2011.
203. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 102: 449-461, 2003.
204. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci USA 101: 10578-10583, 2004.
205. Novinska MS, Rathore V, Newman DK, Newman PJ. Pecam-1. In: Platelets, edited by Michelson AD. Burlington: Academic, 2001, p. 221-230.
206. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78: 387-393, 1991.
207. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 72: 2020-2025, 1988.
208. Nurden A, Nurden P. Advances in our understanding of the molecular basis of disorders of platelet function. J Thromb Haemost 9 Suppl 1: 76-91, 2011.
209. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 91: 9208-9212, 1994.
210. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, Brass LF. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 275: 13502-13509, 2000.
211. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 99: 1293-1304, 2006.
212. Offermanns S. In vivo functions of heterotrimeric G-proteins: studies in G-deficient mice. Oncogene 20: 1635-1642, 2001.
213. Oganesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, Esmon NL, Esmon CT. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem 277: 24851-24854, 2002.
214. Oliver JA, Monroe DM, Church FC, Roberts HR, Hoffman M. Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood 100: 539-546, 2002.
215. Ollivier V, Wang J, Manly D, Machlus KR, Wolberg AS, Jandrot-Perrus M, Mackman N. Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay. Thromb Res 125: 90-96, 2010.
216. Olson ST, Chuang YJ. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med 12: 331-338, 2002.
217. Olson ST, Halvorson HR, Bjork I. Quantitative characterization of the thrombinheparin interaction. Discrimination between specific and nonspecific binding models. J Biol Chem 266: 6342-6352, 1991.
218. Olson ST, Swanson R, Raub-Segall E, Bedsted T, Sadri M, Petitou M, Herault JP, Herbert JM, Bjork I. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin. Thromb Haemost 92: 929-939, 2004.
219. Orfeo T, Butenas S, Brummel-Ziedins KE, Mann KG. The tissue factor requirement in blood coagulation. J Biol Chem 280: 42887-42896, 2005.
220. Ortel TL, vore-Carter D, Quinn-Allen M, Kane WH. Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain. J Biol Chem 267: 4189-4198, 1992.
221. Osterud B, Rao LV, Olsen JO. Induction of tissue factor expression in whole blood: lack of evidence for the presence of tissue factor expression in granulocytes. Thromb Haemost 83: 861-867, 2000.
222. Ostrowska E, Reiser G. Protease-activated receptor (PAR)-induced interleukin-8 production in airway epithelial cells requires activation of MAP kinases p44/42 and JNK. Biochem Biophys Res Commun 366: 1030-1035, 2008.
223. Oury C, Kuijpers MJ, Toth-Zsamboki E, Bonnefoy A, Danloy S, Vreys I, Feijge MA, De Vos R, Vermylen J, Heemskerk JW, Hoylaerts MF. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 101: 3969-3976, 2003.
224. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 108: 1284-1297, 2011.
225. Pauer HU, Renne T, Hemmerlein B, Legler T, Fritzlar S, Adham I, Muller-Esterl W, Emons G, Sancken U, Engel W, Burfeind P. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb Haemost 92: 503-508, 2004.
226. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, Andrade-Gordon P, Frank RD, Mackman N. Role of tissue factor and protease activated receptors in a mouse model of endotoxemia. Blood 103: 1342-1347, 2003.
227. Pendurthi UR, Ghosh S, Mandal SK, Rao LV. Tissue factor activation: is disulfide bond switching a regulatory mechanism? Blood 110: 3900-3908, 2007.
228. Peng W, Quinn-Allen MA, Kane WH. Mutation of hydrophobic residues in the factor Va C1 and C2 domains blocks membrane-dependent prothrombin activation. J Thromb Haemost 3: 351-354, 2005.
229. Peraramelli S, Rosing J, Hackeng TM. TFPI-dependent activities of protein S. Thromb Res 129 Suppl 2: S23-26, 2012.
230. Petrovan RJ, Ruf W. Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa. J Biol Chem 276: 6616-6620, 2001.
231. Plow EW, Pesho MM, Ma YQ. Integrin alpha IIb beta 3. In: Platelets, edited by Michelson AD. Burlington: Academic, 2007, p. 165-184.
232. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 13: 1086-1095, 2007.
233. Pollitt AY, Grygielska B, Leblond B, Desire L, Eble JA, Watson SP. Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac. Blood 115: 2938-2946, 2010.
234. Preissner KT, Reuning U. Vitronectin in vascular context: facets of a multitalented matricellular protein. Semin Thromb Hemost 37: 408-424, 2011.
235. Pugh N, Simpson AM, Smethurst PA, de Groot PG, Raynal N, Farndale RW. Synergism between platelet collagen receptors defined using receptor-specific collagen-mimetic peptide substrata in flowing blood. Blood 115: 5069-5079, 2010.
236. Puy C, Lopez-Sagaseta J, Hermida J, Montes R. The endothelial cells downregulate the generation of factor VIIa through EPCR binding. Br J Haematol 149: 111-117, 2010.
237. Quek LS, Pasquet JM, Hers I, Cornall R, Knight G, Barnes M, Hibbs ML, Dunn AR, Lowell CA, Watson SP. Fyn and Lyn phosphorylate the Fc receptor gamma chain downstream of glycoprotein VI in murine platelets, and Lyn regulates a novel feedback pathway. Blood 96: 4246-4253, 2000.
238. Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 7: 514-520, 2009.
239. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366: 2055-2064, 2012.
240. Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 34: 602-613, 1955.
241. Redondo PC, Salido GM, Pariente JA, Sage SO, Rosado JA. SERCA2b and 3 play a regulatory role in store-operated calcium entry in human platelets. Cell Signal 20: 337-346, 2008.
242. Rehemtulla A, Ruf W, Edgington TS. The integrity of the cysteine 186-cysteine 209 bond of the second disulfide loop of tissue factor is required for binding of factor VII. J Biol Chem 266: 10294-10299, 1991.
243. Reinhardt C, von Bruhl ML, Manukyan D, Grahl L, Lorenz M, Altmann B, Dlugai S, Hess S, Konrad I, Orschiedt L, Mackman N, Ruddock L, Massberg S, Engelmann B. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 118: 1110-1122, 2008.
244. Reitsma PH, Versteeg HH, Middeldorp S. Mechanistic view of risk factors for venous thromboembolism. Arterioscler Thromb Vasc Biol 32: 563-568, 2012.
245. Renne T, Gailani D. Role of Factor XII in hemostasis and thrombosis: clinical implications. Expert Rev Cardiovasc Ther 5: 733-741, 2007.
246. Riddel JP Jr, Aouizerat BE, Miaskowski C, Lillicrap DP. Theories of blood coagulation. J Pediatr Oncol Nurs 24: 123-131, 2007.
247. Riewald M, Kravchenko VV, Petrovan RJ, O'Brien PJ, Brass LF, Ulevitch RJ, Ruf W. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1. Blood 97: 3109-3116, 2001.
248. Riewald M, Petrovan RJ, Donner A, Ruf W. Activated protein C signals through the thrombin receptor PAR1 in endothelial cells. J Endotoxin Res 9: 317-321, 2003.
249. Riewald M, Ruf W. Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor. Proc Natl Acad Sci USA 98: 7742-7747, 2001.
250. Roberts W, Magwenzi S, Aburima A, Naseem KM. Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade. Blood 116: 4297-4306, 2010.
251. Rodriguez AL, Wojcik BM, Wrobleski SK, Myers DD Jr, Wakefield TW, Diaz JA. Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis 33: 371-382, 2012.
252. Romo GM, Dong JF, Schade AJ, Gardiner EE, Kansas GS, Li CQ, McIntire LV, Berndt MC, Lopez JA. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 190: 803-814, 1999.
253. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 7 Suppl 1: 301-304, 2009.
254. Roy S, Paborsky LR, Vehar GA. Self-association of tissue factor as revealed by chemical cross-linking. J Biol Chem 266: 4665-4668, 1991.
255. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 8: 1227-1234, 2002.
256. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 1: 1335-1342, 2003.
257. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5: 31-41, 2007.
258. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 272: 14477-14482, 1997.
259. Santulli RJ, Derian CK, Darrow AL, Tomko KA, Eckardt AJ, Seiberg M, Scarborough RM, Andrade-Gordon P. Evidence for the presence of a protease-activated receptor distinct from the thrombin receptor in human keratinocytes. Proc Natl Acad Sci USA 92: 9151-9155, 1995.
260. Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S. A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 103: 1311-1318, 2004.
261. Savage B, Ruggeri ZM. Platelet thrombus formation in flowing blood. In: Platelets. Burlington: Academic, 2007, p. 359-367.
262. Schmaier AA, Zou Z, Kazlauskas A, Emert-Sedlak L, Fong KP, Neeves KB, Maloney SF, Diamond SL, Kunapuli SP, Ware J, Brass LF, Smithgall TE, Saksela K, Kahn ML. Molecular priming of Lyn by GPVI enables an immune receptor to adopt a hemostatic role. Proc Natl Acad Sci USA 106: 21167-21172, 2009.
263. Schmidt B, Ho L, Hogg PJ. Allosteric disulfide bonds. Biochemistry 45: 7429-7433, 2006.
264. Schmidt VA, Nierman WC, Maglott DR, Cupit LD, Moskowitz KA, Wainer JA, Bahou WF. The human proteinase-activated receptor-3 (PAR-3) gene. Identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets. J Biol Chem 273: 15061-15068, 1998.
265. Schneider M, Brufatto N, Neill E, Nesheim M. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin. J Biol Chem 279: 13340-13345, 2004.
266. Schuepbach RA, Feistritzer C, Brass LF, Riewald M. Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood 111: 2667-2673, 2008.
267. Schwertz H, Tolley ND, Foulks JM, Denis MM, Risenmay BW, Buerke M, Tilley RE, Rondina MT, Harris EM, Kraiss LW, Mackman N, Zimmerman GA, Weyrich AS. Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. J Exp Med 203: 2433-2440, 2006.
268. Senis YA, Tomlinson MG, Ellison S, Mazharian A, Lim J, Zhao Y, Kornerup KN, Auger JM, Thomas SG, Dhanjal T, Kalia N, Zhu JW, Weiss A, Watson SP. The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. Blood 113: 4942-4954, 2009.
269. Sevinsky JR, Rao LV, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factordependent coagulation pathway. J Cell Biol 133: 293-304, 1996.
270. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 11: 288-300, 2010.
271. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 269: 18735-18738, 1994.
272. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 69: 58-178, 1989.
273. Siljander PR, Munnix IC, Smethurst PA, Deckmyn H, Lindhout T, Ouwehand WH, Farndale RW, Heemskerk JW. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood 103: 1333-1341, 2004.
274. Simon DI, Chen Z, Xu H, Li CQ, Dong J, McIntire LV, Ballantyne CM, Zhang L, Furman MI, Berndt MC, Lopez JA. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 192: 193-204, 2000.
275. Smith SA, Choi SH, Davis-Harrison R, Huyck J, Boettcher J, Rienstra CM, Morrissey JH. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 116: 4353-4359, 2010.
276. Stavenuiter F, Dienava-Verdoold I, Boon-Spijker MG, Brinkman HJ, Meijer AB, Mertens K. Factor Seven Activating Protease (FSAP): does it activate factor VII? J Thromb Haemost 10: 859-866, 2012.
277. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 93: 10212-10216, 1996.
278. Steele BM, Harper MT, Macaulay IC, Morrell CN, Perez-Tamayo A, Foy M, Habas R, Poole AW, Fitzgerald DJ, Maguire PB. Canonical Wnt signaling negatively regulates platelet function. Proc Natl Acad Sci USA 106: 19836-19841, 2009.
279. Stegner D, Nieswandt B. Platelet receptor signaling in thrombus formation. J Mol Med 89: 109-121, 2011.
280. Storck J, Kusters B, Zimmermann ER. The tethered ligand receptor is the responsible receptor for the thrombin induced release of von Willebrand factor from endothelial cells (HUVEC). Thromb Res 77: 249-258, 1995.
281. Suzuki-Inoue K, Inoue O, Ozaki Y. Novel platelet activation receptor CLEC-2: from discovery to prospects. J Thromb Haemost 9 Suppl 1: 44-55, 2011.
282. Suzuki J, Umeda M, Sims PJ, Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 468: 834-838, 2010.
283. Suzuki K, Kusumoto H, Deyashiki Y, Nishioka J, Maruyama I, Zushi M, Kawahara S, Honda G, Yamamoto S, Horiguchi S. Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation. EMBO J 6: 1891-1897, 1987.
284. Swords N, Mann KG. Thrombin. In: Hemostasis and Thrombosis, Basic Principles and Clinical Practice, edited by RW Colman, VJ Marder, AW Clowes, JN George. Philadelphia, PA: Lippincott Williams & Wilkins, 2001, p. 171-189.
285. Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 96: 1233-1239, 2005.
286. Szotowski B, Goldin-Lang P, Antoniak S, Bogdanov VY, Pathirana D, Pauschinger M, Dorner A, Kuehl U, Coupland S, Nemerson Y, Hummel M, Poller W, Hetzer R, Schultheiss HP, Rauch U. Alterations in myocardial tissue factor expression and cellular localization in dilated cardiomyopathy. J Am Coll Cardiol 45: 1081-1089, 2005.
287. Tai MM, Furie BC, Furie B. Localization of the metal-induced conformational transition of bovine prothrombin. J Biol Chem 259: 4162-4168, 1984.
288. Taylor FB Jr, Dahlback B, Chang AC, Lockhart MS, Hatanaka K, Peer G, Esmon CT. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood 86: 2642-2652, 1995.
289. Taylor FB Jr, Peer GT, Lockhart MS, Ferrell G, Esmon CT. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 97: 1685-1688, 2001.
290. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G, Esmon CT. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 95: 1680-1686, 2000.
291. Tesselaar ME, Romijn FP, Van DLI, Prins FA, Bertina RM, Osanto S. Microparticleassociated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5: 520-527, 2007.
292. Theoret JF, Yacoub D, Hachem A, Gillis MA, Merhi Y. P-selectin ligation induces platelet activation and enhances microaggregate and thrombus formation. Thromb Res 128: 243-250, 2011.
293. Thiagarajan P, Kelly KL. Exposure of binding sites for vitronectin on platelets following stimulation. J Biol Chem 263: 3035-3038, 1988.
294. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366: 20-33, 2012.
295. Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, Covic L, Kuliopulos A. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137: 332-343, 2009.
296. Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost 38: 469-482, 2012.
297. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 1: 625-631, 2003.
298. Tsiang M, Lentz SR, Sadler JE. Functional domains of membrane-bound human thrombomodulin. EGF-like domains four to six and the serine/threonine-rich domain are required for cofactor activity. J Biol Chem 267: 6164-6170, 1992.
299. Van de Walle GR, Schoolmeester A, Iserbyt BF, Cosemans JM, Heemskerk JW, Hoylaerts MF, Nurden A, Vanhoorelbeke K, Deckmyn H. Activation of alphaIIbbeta3 is a sufficient but also an imperative prerequisite for activation of alpha2beta1 on platelets. Blood 109: 595-602, 2007.
300. Van den Berg YW, Osanto S, Reitsma PH, Versteeg HH. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 119: 924-932, 2012.
301. Van den Hengel LG, Kocaturk B, Reitsma PH, Ruf W, Versteeg HH. Complete abolishment of coagulant activity in monomeric disulfide-deficient tissue fagctor. Blood 118: 3446-3448, 2011.
302. Van der Meijden PE, Munnix IC, Auger JM, Govers-Riemslag JW, Cosemans JM, Kuijpers MJ, Spronk HM, Watson SP, Renne T, Heemskerk JW. Dual role of collagen in factor XII-dependent thrombus formation. Blood 114: 881-890, 2009.
303. Van Nieuw Amerongen GP, Musters RJ, Eringa EC, Sipkema P, van Hinsbergh VW. Thrombin-induced endothelial barrier disruption in intact microvessels: role of RhoA/ Rho kinase-myosin phosphatase axis. Am J Physiol Cell Physiol 294: C1234-C1241, 2008.
304. Varga-Szabo D, Braun A, Nieswandt B. STIM and Orai in platelet function. Cell Calcium 50: 270-278, 2011.
305. Vary TC, Kimball SR. Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol Cell Physiol 262: C445-C452, 1992.
306. Vazzana N, Ranalli P, Cuccurullo C, Davi G. Diabetes mellitus and thrombosis. Thromb Res 129: 371-377, 2012.
307. Versteeg HH, Ruf W. Tissue factor coagulant function is enhanced by protein-disulfide isomerase independent of oxidoreductase activity. J Biol Chem 282: 25416-25424, 2007.
308. Von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, Khandoga A, Tirniceriu A, Coletti R, Kollnberger M, Byrne RA, Laitinen I, Walch A, Brill A, Pfeiler S, Manukyan D, Braun S, Lange P, Riegger J, Ware J, Eckart A, Haidari S, Rudelius M, Schulz C, Echtler K, Brinkmann V, Schwaiger M, Preissner KT, Wagner DD, Mackman N, Engelmann B, Massberg S. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 209: 819-835, 2012.
309. Vu TKH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64: 1057-1068, 1991.
310. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 273: 27176-27181, 1998.
311. Warr TA, Rao LVM, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 75: 1481-1489, 1990.
312. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost 3: 1752-1762, 2005.
313. Watson SP, Herbert JM, Pollitt AY. GPVI and CLEC-2 in hemostasis and vascular integrity. J Thromb Haemost 8: 1456-1467, 2010.
314. Weeterings C, de Groot PG, Adelmeijer J, Lisman T. The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. Blood 112: 3227-3233, 2008.
315. Wei AH, Schoenwaelder SM, Andrews RK, Jackson SP. New insights into the haemostatic function of platelets. Br J Haematol 147: 415-430, 2009.
316. Weiss HJ. Impaired platelet procoagulant mechanisms in patients with bleeding disorders. Semin Thromb Hemost 35: 233-241, 2009.
317. White-Adams TC, Berny MA, Tucker EI, Gertz JM, Gailani D, Urbanus RT, de Groot PG, Gruber A, McCarty OJ. Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc Biol 29: 1602-1607, 2009.
318. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86: 2839-2843, 1989.
319. Wilkinson B, Gilbert HF. Protein disulfide isomerase. Biochim Biophys Acta 1699: 35-44, 2004.
320. Wong C, Liu Y, Yip J, Chand R, Wee JL, Oates L, Nieswandt B, Reheman A, Ni H, Beauchemin N, Jackson DE. CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo. Blood 113: 1818-1828, 2009.
321. Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF. Activation of Rap1B by G(i) family members in platelets. J Biol Chem 277: 23382-23390, 2002.
322. Wu KK, Aleksic N, Ballantyne CM, Ahn C, Juneja H, Boerwinkle E. Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease. Circulation 107: 1729-1732, 2003.
323. Xu J, Qu D, Esmon NL, Esmon CT. Metalloproteolytic release of endothelial cell protein C receptor. J Biol Chem 275: 6038-6044, 2000.
324. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. Extracellular histones are major mediators of death in sepsis. Nat Med 15: 1318-1321, 2009.
325. Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K. A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 8: 817-827, 2010.
326. Yang XV, Banerjee Y, Fernandez JA, Deguchi H, Xu X, Mosnier LO, Urbanus RT, de Groot PG, White-Adams TC, McCarty OJ, Griffin JH. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci USA 106: 274-279, 2009.
327. Ye F, Petrich BG. Kindlin: helper, co-activator, or booster of talin in integrin activation? Curr Opin Hematol 18: 356-360, 2011.
328. Yoshimori T, Semba T, Takemoto H, Akagi S, Yamamoto A, Tashiro Y. Protein disulfide-isomerase in rat exocrine pancreatic cells is exported from the endoplasmic reticulum despite possessing the retention signal. J Biol Chem 265: 15984-15990, 1990.
329. Zheng X, Li W, Gu JM, Qu D, Ferrell GL, Esmon NL, Esmon CT. Effects of membrane and soluble EPCR on the hemostatic balance and endotoxemia in mice. Blood 109: 1003-1009, 2007.
330. Zhou A, Huntington JA, Pannu NS, Carrell RW, Read RJ. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10: 541-544, 2003.
331. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 62: 971-988, 2005.
332. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89: 1121-1132, 1997.